NCT00401830 - Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Fibromyalgia Syndrome

Interventions

DRUG

Lacosamide

Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg

OTHER

Placebo

Matching placebo tablet administered twice daily

Trial Locations (25)

20301

Brockton

21045

Columbia

21702

Frederick

23294

Richmond

27103

Winston-Salem

28210

Charlotte

29445

Goose Creek

30033

Decatur

Memphis

33064

Deerfield Beach

33334

Fort Lauderdale

33614

Tampa

33916

Fort Myers

42431

Madisonville

43623

Toledo

44260

Mogadore

47714

Evansville

61614

Peoria

78213

San Antonio

92705

Santa Ana

94598

Walnut Creek

98033

Kirkland

Unknown

Litchfield Park

Athens

San Antonio